Related Experiment Video
Updated: Oct 19, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells
V L Locke1, R A Davey, M W Davey
1Department of Cell and Molecular Biology, University of Technology, Sydney, Gore Hill, NSW, Australia.
Abstract:
Relative to the commonly used anthracyclines, little is known about idarubicin and the development of multidrug resistance. We have previously shown the K562/IDA subline resulting from intermittent treatment of the K562 human leukaemia cell line with 20 ng/ml idarubicin did not develop multidrug resistance but became more sensitive to etoposide. Additional similar treatments of this subline produced the K562/IDA20 subline which partially retained its etoposide sensitivity although these cells expressed P-glycoprotein and were resistant to paclitaxel. Sensitization to etoposide was associated with increased decatenation activity of topoisomerase II, although there were no changes in topoisomerase IIalpha expression or formation of etoposide-dependent cleavable complexes. In comparison, the K562/IDA10 subline produced by intermittent treatment of the K562 cells, firstly with 5 ng/ml then 10 ng/ml idarubicin, showed no detectable expression of P-glycoprotein, decreased topoisomerase IIalpha expression and increased resistance to etoposide and amsacrine, but not to idarubicin or genistein. Even though intermittent treatment with idarubicin caused increased drug resistance in both sublines, they remained sensitive to idarubicin. Therefore the potential of idarubicin as a substitute for other anthracyclines in the treatment of cancer warrants further investigation.
Insights
Idarubicin treatment of leukemia cells revealed complex resistance patterns. Despite developing resistance to other drugs, cells remained sensitive to idarubicin, suggesting its potential as an alternative chemotherapy agent.
Area of Science:
- Biochemistry
- Pharmacology
- Cancer Biology
Background:
- Limited knowledge exists regarding idarubicin's role in multidrug resistance compared to other anthracyclines.
- Previous studies showed K562/IDA cells, treated with idarubicin, gained sensitivity to etoposide without developing multidrug resistance.
Purpose of the Study:
- To investigate the effects of intermittent idarubicin treatment on K562 human leukemia cell line resistance.
- To explore the mechanisms underlying altered drug sensitivity and resistance in idarubicin-exposed cell lines.
Main Methods:
- Development of K562/IDA20 and K562/IDA10 sublines through intermittent idarubicin exposure.
- Assessment of multidrug resistance markers, including P-glycoprotein expression.
- Evaluation of topoisomerase II activity, expression, and etoposide-dependent complex formation.
- Testing sensitivity to various chemotherapy drugs, including etoposide, paclitaxel, amsacrine, idarubicin, and genistein.
Main Results:
- K562/IDA20 cells showed partial etoposide sensitivity, P-glycoprotein expression, and paclitaxel resistance.
- Increased topoisomerase II decatenation activity was observed in K562/IDA20 cells, without changes in topoisomerase IIalpha expression or cleavable complex formation.
- K562/IDA10 cells exhibited no detectable P-glycoprotein, decreased topoisomerase IIalpha expression, and resistance to etoposide and amsacrine.
- Both sublines remained sensitive to idarubicin, despite developing resistance to other agents.
Conclusions:
- Intermittent idarubicin treatment induces complex drug resistance profiles in leukemia cells.
- Despite resistance to other chemotherapeutics, sensitivity to idarubicin is maintained.
- Idarubicin's potential as a substitute for other anthracyclines in cancer treatment warrants further investigation.
Related Concept Videos
01:16Drug toxicity: Idiosyncratic Reactions
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase